Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01397695 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of California, San Diego